[1] |
Stavropoulos PG, Soura E, Antoniou C. Drug⁃induced pemphigoid: a review of the literature[J]. J Eur Acad Dermatol Venereol, 2014,28(9):1133⁃1140. doi: 10.1111/jdv.12366.
|
[2] |
Lee JJ, Downham TF 2nd. Furosemide⁃induced bullous pemphigoid: case report and review of literature[J]. J Drugs Dermatol, 2006,5(6):562⁃564.
|
[3] |
Bean SF, Good RA, Windhorst DB. Bullous pemphigoid in an 11⁃year⁃old boy[J]. Arch Dermatol, 1970,102(2):205⁃208.
|
[4] |
Neri I, Greco A, Bassi A, et al. Bullous pemphigoid in infant post vaccination: myth or reality?[J]. Int J Immunopathol Pharmacol, 2016,29(2):295⁃299. doi: 10.1177/0394632015603796.
|
[5] |
Cortés⁃Pinto C, Baradad Brusau M, Vilardell Vilellas F, et al. Bullous pemphigoid in a 3⁃month⁃old infant after vaccination[J]. Clin Exp Dermatol, 2019,44(3):341⁃343. doi: 10.1111/ced.13752.
|
[6] |
Baroero L, Coppo P, Bertolino L, et al. Three case reports of post immunization and post viral bullous pemphigoid: looking for the right trigger[J]. BMC Pediatr, 2017,17(1):60. doi: 10.1186/s12887⁃017⁃0813⁃0.
|
[7] |
Walmsley N, Hampton P. Bullous pemphigoid triggered by swine flu vaccination: case report and review of vaccine triggered pemphigoid[J]. J Dermatol Case Rep, 2011,5(4):74⁃76. doi: 10. 3315/jdcr.2011.1081.
|
[8] |
Kawaguchi Y, Shimauchi R, Nishibori N, et al. Dipeptidyl peptidase⁃4 inhibitors⁃associated bullous pemphigoid: a retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients[J]. J Diabetes Investig, 2019,10(2):392⁃398. doi: 10.1111/jdi.12877.
|
[9] |
Béné J, Moulis G, Bennani I, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case⁃noncase study in the French Pharmacovigilance Database[J]. Br J Dermatol, 2016,175(2):296⁃301. doi: 10.1111/bjd.14601.
|
[10] |
Izumi K, Nishie W, Mai Y, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid[J]. J Invest Dermatol, 2016,136(11):2201⁃2210. doi: 10.1016/j.jid.2016.06.622.
|
[11] |
Chijiwa C, Takeoka S, Kamata M, et al. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase⁃4 inhibitor⁃related bullous pemphigoid[J]. J Dermatol, 2018,45(5):596⁃599. doi: 10.1111/1346⁃8138.14245.
|
[12] |
García⁃Díez I, Ivars⁃Lleó M, López⁃Aventín D, et al. Bullous pemphigoid induced by dipeptidyl peptidase⁃4 inhibitors. Eight cases with clinical and immunological characterization[J]. Int J Dermatol, 2018,57(7):810⁃816. doi: 10.1111/ijd.14005.
|
[13] |
Skandalis K, Spirova M, Gaitanis G, et al. Drug⁃induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase⁃IV inhibitors plus metformin[J]. J Eur Acad Dermatol Venereol, 2012,26(2):249⁃253. doi: 10.1111/j.1468⁃3083.2011. 04062.x.
|
[14] |
Ameglio F, D′Auria L, Bonifati C, et al. Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: relationships with disease intensity[J]. Br J Dermatol, 1998,138(4):611⁃614. doi: 10.1046/j.1365⁃2133.1998.02169.x.
|
[15] |
Nin M, Tokunaga D, Ishii N, et al. Case of coexisting psoriatic arthritis and bullous pemphigoid improved by etanercept[J]. J Dermatol, 2013,40(1):55⁃56. doi: 10.1111/j.1346⁃8138.2012. 01659.x.
|
[16] |
Ricci M, Zauli S, Zelante A, et al. Bullous pemphigoid occurring under anti⁃tumor necrosis factor⁃α therapy[J]. Int J Colorectal Dis, 2014,29(12):1573⁃1574. doi: 10.1007/s00384⁃014⁃1924⁃9.
|
[17] |
Boussemart L, Jacobelli S, Batteux F, et al. Autoimmune bullous skin diseases occurring under anti⁃tumor necrosis factor therapy: two case reports[J]. Dermatology, 2010,221(3):201⁃205. doi: 10. 1159/000318008.
|
[18] |
Kluk J, Goulding JM, Bhat J, et al. Drug⁃induced bullous pemphigoid: cases triggered by intravenous iodine and etanercept[J]. Clin Exp Dermatol, 2011,36(8):871⁃873. doi: 10.1111/j. 1365⁃2230.2011.04102.x.
|
[19] |
Monnier⁃Murina K, Du Thanh A, Merlet⁃Albran S, et al. Bullous pemphigoid occurring during efalizumab treatment for psoriasis: a paradoxical auto⁃immune reaction?[J]. Dermatology, 2009,219(1):89⁃90. doi: 10.1159/000207792.
|
[20] |
Bordignon M, Belloni⁃Fortina A, Pigozzi B, et al. Bullous pemphigoid during long⁃term TNF⁃alpha blocker therapy[J]. Dermatology, 2009,219(4):357⁃358. doi: 10.1159/000243805.
|
[21] |
Liu LY, Bates ME, Jarjour NN, et al. Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF⁃alpha[J]. J Immunol, 2007,179(7):4840⁃4848. doi: 10. 4049/jimmunol.179.7.4840.
|
[22] |
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy[J]. Am J Clin Dermatol, 2018,19(3):345⁃361. doi: 10.1007/s40257⁃017⁃0336⁃3.
|
[23] |
Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti⁃PD⁃1 and anti⁃PD⁃L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy[J]. J Am Acad Dermatol, 2018,79(6):1081⁃1088. doi: 10.1016/j.jaad. 2018.07.008.
|
[24] |
Lopez AT, Khanna T, Antonov N, et al. A review of bullous pemphigoid associated with PD⁃1 and PD⁃L1 inhibitors[J]. Int J Dermatol, 2018,57(6):664⁃669. doi: 10.1111/ijd.13984.
|
[25] |
Naidoo J, Schindler K, Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD⁃1 and PD⁃L1[J]. Cancer Immunol Res, 2016,4(5):383⁃389. doi: 10.1158/2326⁃6066.CIR⁃15⁃0123.
|